FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4308796306> ?p ?o ?g. }

• W4308796306 endingPage "67" @default.
• W4308796306 startingPage "61" @default.
• W4308796306 abstract "Background Despite the advances in the management of advanced non–small cell lung cancer (NSCLC), the access to genetic profiling and target therapies remains a challenge in Latin America, even in countries with a higher rate of targetable mutations. The aim of this study is to evaluate the clinical outcomes of anti-epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKI) treatment in a Peruvian real-world setting. Methods This is a retrospective study of recurrent or advanced NSCLC EGFR mutated patients diagnosed and treated with anti-EGFR TKI at Instituto Nacional de Enfermedades Neoplásicas (INEN) between January 1, 2015 to December 31, 2020. The outcomes were objective response rate (ORR), progression free survival (PFS), and overall survival (OS). Results We identify 613 stage IV or recurrent NSCLC patients who were tested for EGFR mutations and found a pathogenic mutation in 39.5% of patients. Only 51.2% of them received anti-EGFR TKI as institutional treatment. ORR was 58%, after median follow-up of 32 months, the estimated median PFS was 13.9 months (11.1–16.7 months), and the estimated median OS was 21.7 months (18.5–24.9 months). No differences were found in PFS according to line of treatment or brain metastases at diagnosis (p = 0.46 and p = 0.07, respectively), respect to OS there were no differences line of treatment (p = 0.12), significant difference were found in presence of brain metastases (p = 0.006). Conclusion Our study demonstrates that erlotinib for advanced NSCLC harboring EGFR-activating mutations is effective even in patients usually excluded from clinical trial, like those previously exposed to one or more lines of chemotherapy or with brain metastases." @default.
• W4308796306 created "2022-11-15" @default.
• W4308796306 creator A5014318991 @default.
• W4308796306 creator A5019150525 @default.
• W4308796306 creator A5029356961 @default.
• W4308796306 creator A5046876907 @default.
• W4308796306 creator A5053786511 @default.
• W4308796306 creator A5070250906 @default.
• W4308796306 creator A5079381386 @default.
• W4308796306 creator A5082878000 @default.
• W4308796306 date "2022-11-11" @default.
• W4308796306 modified "2023-10-18" @default.
• W4308796306 title "Real‐world outcomes of <scp>anti‐EGFR</scp> therapy in advanced non–small cell lung cancer <scp>EGFR</scp> mutated in Peru" @default.
• W4308796306 cites W1986606168 @default.
• W4308796306 cites W2040178944 @default.
• W4308796306 cites W2040299716 @default.
• W4308796306 cites W2065477010 @default.
• W4308796306 cites W2096198395 @default.
• W4308796306 cites W2111662961 @default.
• W4308796306 cites W2133149289 @default.
• W4308796306 cites W2166084034 @default.
• W4308796306 cites W2171755671 @default.
• W4308796306 cites W2581391138 @default.
• W4308796306 cites W2611834130 @default.
• W4308796306 cites W2767275374 @default.
• W4308796306 cites W2770828094 @default.
• W4308796306 cites W2774701235 @default.
• W4308796306 cites W2793327490 @default.
• W4308796306 cites W2943846365 @default.
• W4308796306 cites W2947223357 @default.
• W4308796306 cites W2949683238 @default.
• W4308796306 cites W2984224267 @default.
• W4308796306 cites W3031493441 @default.
• W4308796306 cites W3033495201 @default.
• W4308796306 cites W3048896255 @default.
• W4308796306 cites W3095351897 @default.
• W4308796306 cites W3128646645 @default.
• W4308796306 cites W3214015044 @default.
• W4308796306 cites W4211059596 @default.
• W4308796306 cites W4308796306 @default.
• W4308796306 doi "https://doi.org/10.1111/1759-7714.14714" @default.
• W4308796306 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36369763" @default.
• W4308796306 hasPublicationYear "2022" @default.
• W4308796306 type Work @default.
• W4308796306 citedByCount "1" @default.
• W4308796306 countsByYear W43087963062022 @default.
• W4308796306 crossrefType "journal-article" @default.
• W4308796306 hasAuthorship W4308796306A5014318991 @default.
• W4308796306 hasAuthorship W4308796306A5019150525 @default.
• W4308796306 hasAuthorship W4308796306A5029356961 @default.
• W4308796306 hasAuthorship W4308796306A5046876907 @default.
• W4308796306 hasAuthorship W4308796306A5053786511 @default.
• W4308796306 hasAuthorship W4308796306A5070250906 @default.
• W4308796306 hasAuthorship W4308796306A5079381386 @default.
• W4308796306 hasAuthorship W4308796306A5082878000 @default.
• W4308796306 hasBestOaLocation W43087963061 @default.
• W4308796306 hasConcept C121608353 @default.
• W4308796306 hasConcept C126322002 @default.
• W4308796306 hasConcept C143998085 @default.
• W4308796306 hasConcept C2776256026 @default.
• W4308796306 hasConcept C2778087573 @default.
• W4308796306 hasConcept C2779438470 @default.
• W4308796306 hasConcept C2780739268 @default.
• W4308796306 hasConcept C2781230642 @default.
• W4308796306 hasConcept C3019894029 @default.
• W4308796306 hasConcept C71924100 @default.
• W4308796306 hasConceptScore W4308796306C121608353 @default.
• W4308796306 hasConceptScore W4308796306C126322002 @default.
• W4308796306 hasConceptScore W4308796306C143998085 @default.
• W4308796306 hasConceptScore W4308796306C2776256026 @default.
• W4308796306 hasConceptScore W4308796306C2778087573 @default.
• W4308796306 hasConceptScore W4308796306C2779438470 @default.
• W4308796306 hasConceptScore W4308796306C2780739268 @default.
• W4308796306 hasConceptScore W4308796306C2781230642 @default.
• W4308796306 hasConceptScore W4308796306C3019894029 @default.
• W4308796306 hasConceptScore W4308796306C71924100 @default.
• W4308796306 hasIssue "1" @default.
• W4308796306 hasLocation W43087963061 @default.
• W4308796306 hasLocation W43087963062 @default.
• W4308796306 hasLocation W43087963063 @default.
• W4308796306 hasOpenAccess W4308796306 @default.
• W4308796306 hasPrimaryLocation W43087963061 @default.
• W4308796306 hasRelatedWork W1480640671 @default.
• W4308796306 hasRelatedWork W1977841344 @default.
• W4308796306 hasRelatedWork W2015910003 @default.
• W4308796306 hasRelatedWork W2037082948 @default.
• W4308796306 hasRelatedWork W2060263774 @default.
• W4308796306 hasRelatedWork W2186047679 @default.
• W4308796306 hasRelatedWork W2345394748 @default.
• W4308796306 hasRelatedWork W2589817436 @default.
• W4308796306 hasRelatedWork W2734557114 @default.
• W4308796306 hasRelatedWork W4308796306 @default.
• W4308796306 hasVolume "14" @default.
• W4308796306 isParatext "false" @default.
• W4308796306 isRetracted "false" @default.
• W4308796306 workType "article" @default.